Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2002

01-02-2002 | Commentary

BAD: a good therapeutic target?

Authors: Andrea B Motoyama, Nancy E Hynes

Published in: Breast Cancer Research | Issue 1/2002

Login to get access

Abstract

The major goal in cancer treatment is the eradication of tumor cells. Under stress conditions, normal cells undergo apoptosis; this property is fortunately conserved in some tumor cells, leading to their death as a result of chemotherapeutic and/or radiation-induced stress. Many malignant cells, however, have developed ways to subvert apoptosis, a characteristic that constitutes a major clinical problem. Gilmore et al. recently described the ability of ZD1839, a small-molecule inhibitor of the epidermal growth factor receptor (EGFR), to induce apoptosis of mammary cells that are dependent upon growth factors for survival. Furthermore, they showed that the major effector of the EGFR-targeted therapy is BAD, a widely expressed BCL-2 family member. These results are promising in light of the role of the EGFR in breast cancer development.
Literature
1.
Gilmore A, Valentijn A, Wang P, Ranger A, Bundred N, O'Hare M, Wakeling A, Korsmeyer S, Streuli C: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 2002, 277: 27643-27650. 10.1074/jbc.M108863200.CrossRefPubMed
2.
Olayioye M, Neve R, Lane H, Hynes N: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093/emboj/19.13.3159.CrossRefPubMedPubMedCentral
3.
Shawver L, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9.CrossRefPubMed
4.
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19: 6550-6565. 10.1038/sj.onc.1204082.CrossRefPubMed
5.
Van Obberghen E, Baron V, Delahaye L, Emanuelli B, Filippa N, Giorgetti-Peraldi S, Lebrun P, Mothe-Satney I, Peraldi P, Rocchi S, Sawka-Verhelle D, Tartare-Deckert S, Giudicelli J: Surfing the insulin signaling web. Eur J Clin Invest. 2001, 31: 966-977. 10.1046/j.1365-2362.2001.00896.x.CrossRefPubMed
6.
Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000, 2: 170-175. 10.1186/bcr50.CrossRefPubMedPubMedCentral
7.
Igney F, Krammer P: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002, 2: 277-288. 10.1038/nrc776.CrossRefPubMed
8.
Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002, 2: 183-192. 10.1016/S1535-6108(02)00127-7.CrossRefPubMed
9.
Bonni A, Brunet A, West A, Datta S, Takasu M, Greenberg M: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999, 286: 1358-1362. 10.1126/science.286.5443.1358.CrossRefPubMed
10.
Shimamura A, Ballif B, Richards S, Blenis J: Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol. 2000, 10: 127-135. 10.1016/S0960-9822(00)00310-9.CrossRefPubMed
11.
Zhou X, Liu Y, Payne G, Lutz R, Chittenden T: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem. 2000, 275: 25046-25051. 10.1074/jbc.M002526200.CrossRefPubMed
12.
Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg M: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.CrossRefPubMed
13.
Harada H, Andersen J, Mann M, Terada N, Korsmeyer S: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001, 98: 9666-9670. 10.1073/pnas.171301998.CrossRefPubMedPubMedCentral
14.
Dramsi S, Scheid M, Maiti A, Hojabrpour P, Chen X, Schubert K, Goodlett D, Aebersold R, Duronio V: Identification of a novel phosphorylation site, Ser-170, as a regulator of bad pro-apoptotic activity. J Biol Chem. 2002, 277: 6399-6405. 10.1074/jbc.M109990200.CrossRefPubMed
15.
Zha J, Harada H, Yang E, Jockel J, Korsmeyer S: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996, 87: 619-628. 10.1016/S0092-8674(00)81382-3.CrossRefPubMed
16.
Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata J, Wang H, Shabaik A, Tudor G, Krajewski S, Myers T, Johnson G, Sausville E, Reed J: Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol. 1998, 152: 51-61.PubMedPubMedCentral
17.
Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001, 7: 2958-2970.PubMed
18.
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001, 21: 499-512. 10.1002/med.1022.CrossRefPubMed
19.
Lynch D, Yang X: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002, 29: 47-50. 10.1053/sonc.2002.31522.CrossRefPubMed
20.
Brandt R, Wong A, Hynes N: Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene. 2001, 20: 5459-5465. 10.1038/sj.onc.1204709.CrossRefPubMed
21.
Bruns C, Solorzano C, Harbison M, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler I: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60: 2926-2935.PubMed
22.
Holinger E, Chittenden T, Lutz R: Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem. 1999, 274: 13298-13304. 10.1074/jbc.274.19.13298.CrossRefPubMed
23.
Cosulich S, Worrall V, Hedge P, Green S, Clarke P: Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol. 1997, 7: 913-920. 10.1016/S0960-9822(06)00410-6.CrossRefPubMed
24.
Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell. 2002, 9: 1005-1016.CrossRefPubMed
Metadata
Title
BAD: a good therapeutic target?
Authors
Andrea B Motoyama
Nancy E Hynes
Publication date
01-02-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr552

Other articles of this Issue 1/2002

Breast Cancer Research 1/2002 Go to the issue

Commentary

Complex roles for telomeres and telomerase in breast carcinogenesis

Commentary

Expression profiling to predict outcome in breast cancer: the influence of sample selection

Research article

Functional and molecular characterisation of mammary side population cells

Review

Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions

Review

Regulation of BRCA1 expression and its relationship to sporadic breast cancer

Letter

Expression profiling predicts outcome in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits